NINDS, NICHD, NIDCD, and NIDDK invite grant applications to develop innovative therapies and tools for screenable disorders in newborns.
The goal of newborn screening is to detect potentially fatal or disabling conditions in newborns, thereby providing a window of opportunity for early treatment, often while the child is still asymptomatic. Such early detection and treatment can have a profound impact on the clinical severity of the condition in the affected child. This initiative supports the development of beneficial treatments for infants that have been identified through newborn screening as having potentially fatal or disabling conditions.
Potential applicants should contact Dr. John Porter, program director, Neurogenetics, NINDS, at 301-496-5745 or email@example.com. For more information visit http://grants.nih.gov/grants/guide/pa-files/PAR-10-230.html.